1.The dose proportionality and bioavailability of the potential anti-inflammatory and neuroprotec-tive JNK inhibitor 11H-indeno[1,2-b]quinoxalin-11-one oxime (IQ-1) were evaluated by comparing pharmacokinetic parameters after single oral (25, 50 and 100mg/kg) and intravenous (1mg/kg) IQ-1 administration in rats.2. IQ-1 and its major metabolite ketone 11H-indeno[1,2-b]quinoxalin-11-one (IQ-18) were isolated from plasma samples by liquid-liquid extraction. IQ-1 (E-isomer) and IQ-18 were simultaneously quantified in plasma by the validated method of liquid chromatography with triple quadrupole mass spectrometry (HPLC-MS/MS).3. The absolute bioavailability of IQ-1 was <1.5%. Cmax values were 24.72 +/- 4.30, 25.66 +/- 7.11 and 37.61 +/- 3.53ng/mL after single oral administration of IQ-1 at doses of 25, 50 and 100mg/kg, respectively. IQ-1 exhibited dose proportionality at 50-100mg/kg dose levels, whereas its pharma-cokinetics was not dose proportional over the range of 25-50mg/kg. IQ-18 demonstrated the invariance of the dose-normalized Cmax.4.In this study we systematically elucidated the absorption characteristics of IQ-1 in rat gastrointes-tinal tract and provided better understanding of IQ-1 pharmacology for the future development of a new formulations and therapeutic optimisation.
1 August 2016 in Bulletin of Experimental Biology and Medicine